Identification of Candidate Genes and Therapeutic Agents for Light Chain Amyloidosis Based on Bioinformatics Approach

References

• Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387(10038):2641–2654. doi:10.1016/S0140-6736(15)01274-X26719234
   PubMed Web of Science ®Google Scholar
• Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29(14):1924–1933. doi:10.1200/JCO.2010.32.227121483018
   PubMed Web of Science ®Google Scholar
• Rosenzweig M, Landau H. Light chain (AL) amyloidosis: update on diagnosis and management. J Hematol Oncol. 2011;4:47. doi:10.1186/1756-8722-4-4722100031
   PubMed Web of Science ®Google Scholar
• Cohen AD, Comenzo RL. Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy. Hematol Am Soc Hemat Educ Program. 2010;2010:287–294. doi:10.1182/asheducation-2010.1.287
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr., Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546–1558. doi:10.1126/science.123512223539594
   PubMed Web of Science ®Google Scholar
• Nannini M, Pantaleo MA, Maleddu A, Astolfi A, Formica S, Biasco G. Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives. Cancer Treat Rev. 2009;35(3):201–209. doi:10.1016/j.ctrv.2008.10.00619081199
   PubMed Web of Science ®Google Scholar
• Guo Y, Bao Y, Ma M, Yang W. Identification of key candidate genes and pathways in colorectal cancer by integrated bioinformatical analysis. Int J Mol Sci. 2017;18(4). doi:10.3390/ijms18040722
   Web of Science ®Google Scholar
• Fang E, Zhang X, Wang Q, Wang D. Identification of prostate cancer hub genes and therapeutic agents using bioinformatics approach. Cancer Biomarkers. 2017;20(4):553–561. doi:10.3233/CBM-17036228800317
   PubMed Web of Science ®Google Scholar
• Zhang K, Xu Z, Sun Z. Identification of the key genes connected with plasma cells of multiple myeloma using expression profiles. Onco Targets Ther. 2015;8:1795–1803. doi:10.2147/OTT26229487
   PubMed Web of Science ®Google Scholar
• Horimoto K, Toh H. Statistical estimation of cluster boundaries in gene expression profile data. Bioinformatics. 2001;17(12):1143–1151. doi:10.1093/bioinformatics/17.12.114311751222
   PubMed Web of Science ®Google Scholar
• Paiva B, Martinez-Lopez J, Corchete LA, et al. Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis. Blood. 2016;127(24):3035–3039. doi:10.1182/blood-2015-10-67309527069257
   PubMed Web of Science ®Google Scholar
• Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249–264. doi:10.1093/biostatistics/4.2.24912925520
   PubMed Web of Science ®Google Scholar
• Gautier L, Cope L, Bolstad BM, Irizarry RA. affy–analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004;20(3):307–315. doi:10.1093/bioinformatics/btg40514960456
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. doi:10.1093/nar/gkv00725605792
   PubMed Web of Science ®Google Scholar
• Dennis G Jr., Sherman BT, Hosack DA, et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003;4(5):P3. doi:10.1186/gb-2003-4-5-p312734009
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Franceschini A, Wyder S, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43(Database issue):D447–452. doi:10.1093/nar/gku100325352553
   PubMed Web of Science ®Google Scholar
• Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504. doi:10.1101/gr.123930314597658
   PubMed Web of Science ®Google Scholar
• Bandettini WP, Kellman P, Mancini C, et al. MultiContrast Delayed Enhancement (MCODE) improves detection of subendocardial myocardial infarction by late gadolinium enhancement cardiovascular magnetic resonance: a clinical validation study. J Cardiovasc Magn Reson. 2012;14:83. doi:10.1186/1532-429X-14-8323199362
   PubMed Web of Science ®Google Scholar
• Lamb J, Crawford ED, Peck D, et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929–1935. doi:10.1126/science.113293917008526
   PubMed Web of Science ®Google Scholar
• van der Bliek AM, Sedensky MM, Morgan PG. Cell biology of the mitochondrion. Genetics. 2017;207(3):843–871. doi:10.1534/genetics.117.30026229097398
   PubMed Web of Science ®Google Scholar
• Pelletier J, Thomas G, Volarevic S. Ribosome biogenesis in cancer: new players and therapeutic avenues. Nat Rev Cancer. 2018;18(1):51–63. doi:10.1038/nrc.2017.10429192214
   PubMed Web of Science ®Google Scholar
• Bierhaus A, Humpert PM, Morcos M, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med. 2005;83(11):876–886. doi:10.1007/s00109-005-0688-716133426
   PubMed Web of Science ®Google Scholar
• Bywater MJ, Poortinga G, Sanij E, et al. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell. 2012;22(1):51–65. doi:10.1016/j.ccr.2012.05.01922789538
   PubMed Web of Science ®Google Scholar
• Bashan A, Yonath A. Correlating ribosome function with high-resolution structures. Trends Microbiol. 2008;16(7):326–335. doi:10.1016/j.tim.2008.05.00118547810
   PubMed Web of Science ®Google Scholar
• Burdelski C, Jakani-Karimi N, Jacobsen F, et al. IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: a tissue microarray study on 8877 human cancers and normal tissues. Oncol Rep. 2018;39(1):3–12. doi:10.3892/or.2017.607229115542
   PubMed Web of Science ®Google Scholar
• Jeng YM, Chang CC, Hu FC, et al. RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology. 2008;48(4):1118–1127. doi:10.1002/hep.2245918802962
   PubMed Web of Science ®Google Scholar
• Shubina MY, Musinova YR, Sheval EV. Proliferation, cancer, and aging-novel functions of the nucleolar methyltransferase fibrillarin? Cell Biol Int. 2018;42(11):1463–1466. doi:10.1002/cbin.v42.1130080298
   PubMed Web of Science ®Google Scholar
• Marcel V, Ghayad SE, Belin S, et al. p53 acts as a safeguard of translational control by regulating fibrillarin and rRNA methylation in cancer. Cancer Cell. 2013;24(3):318–330. doi:10.1016/j.ccr.2013.08.01324029231
   PubMed Web of Science ®Google Scholar
• El Hassouni B, Sarkisjan D, Vos JC, Giovannetti E, Peters GJ. Targeting the ribosome biogenesis key molecule fibrillarin to avoid chemoresistance. Curr Med Chem. 2018.
   Web of Science ®Google Scholar
• Zhu Y, Hou H, Rezai-Zadeh K, et al. CD45 deficiency drives amyloid-beta peptide oligomers and neuronal loss in Alzheimer’s disease mice. J Neurosci. 2011;31(4):1355–1365. doi:10.1523/JNEUROSCI.3268-10.201121273420
   PubMed Web of Science ®Google Scholar
• Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007;7(9):678–689. doi:10.1038/nri215617717539
   PubMed Web of Science ®Google Scholar
• Sandor N, Lukacsi S, Ungai-SAL Amyloidosisnki R, et al. CD11c/CD18 dominates adhesion of human monocytes, macrophages and dendritic cells over CD11b/CD18. PLoS ONE. 2016;11(9):e0163120. doi:10.1371/journal.pone.016312027658051
   PubMed Web of Science ®Google Scholar
• Diamond MS, Staunton DE, de Fougerolles AR, et al. ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18). J Cell Biol. 1990;111(6 Pt 2):3129–3139. doi:10.1083/jcb.111.6.31291980124
   PubMed Web of Science ®Google Scholar
• Ihanus E, Uotila L, Toivanen A, et al. Characterization of ICAM-4 binding to the I domains of the CD11a/CD18 and CD11b/CD18 leukocyte integrins. Eur J Biochem. 2003;270(8):1710–1723. doi:10.1046/j.1432-1033.2003.03528.x12694184
   PubMedGoogle Scholar
• Springer TA, Dustin ML. Integrin inside-out signaling and the immunological synapse. Curr Opin Cell Biol. 2012;24(1):107–115. doi:10.1016/j.ceb.2011.10.00422129583
   PubMed Web of Science ®Google Scholar
• Schmid MC, Khan SQ, Kaneda MM, et al. Integrin CD11b activation drives anti-tumor innate immunity. Nat Commun. 2018;9(1):5379. doi:10.1038/s41467-018-07387-430568188
   PubMed Web of Science ®Google Scholar
• Vorup-Jensen T, Jensen RK. Structural immunology of complement receptors 3 and 4. Front Immunol. 2018;9:2716. doi:10.3389/fimmu.2018.0271630534123
   PubMed Web of Science ®Google Scholar
• Santo L, Hideshima T, Cirstea D, et al. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin Cancer Res. 2011;17(10):3259–3271. doi:10.1158/1078-0432.CCR-10-301221430070
   PubMed Web of Science ®Google Scholar
• Podar K, Tai YT, Davies FE, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2001;98(2):428–435. doi:10.1182/blood.V98.2.42811435313
   PubMed Web of Science ®Google Scholar
• Jourdan E, Leblond V, Maisonneuve H, et al. A multicenter phase II study of single-agent enzastaurin in previously treated multiple myeloma. Leuk Lymphoma. 2014;55(9):2013–2017. doi:10.3109/10428194.2013.86106624180331
   PubMed Web of Science ®Google Scholar
• Hay AE, Murugesan A, DiPasquale AM, et al. A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191. Leuk Lymphoma. 2016;57(6):1463–1466. doi:10.3109/10428194.2015.109192726376958
   PubMed Web of Science ®Google Scholar
• Kraus M, Malenke E, Gogel J, et al. Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis. Mol Cancer Ther. 2008;7(7):1940–1948. doi:10.1158/1535-7163.MCT-07-237518645004
   PubMed Web of Science ®Google Scholar